Kinetic And Pharmacokinetic Analysis Of Treosulfan And Its Biologically Active Mono- And Diepoxytransformers | 10161
Journal of Analytical & Bioanalytical Techniques
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Treosulfan (TREO) is an alkylating agent, registered as ovastat. Presently, TREO is applied as a promising meloablative agent
with low organ toxicity. In physiological conditions it undergoes pH-dependent transformation into monoepoxy-(S,S-
EBDM) and diepoxy-(S,S-DEB) transformers. Kinetics of the parent drug is generally known, but not its active transformers.
The aim of the study was assessment of kinetic and pharmacokinetic parameters of S,S-EBDM as well as SS-DEB and
explanation of reasons of low concentrations of the transformers in patients receiving high doses of TREO as a part of conditioning
regimen before hematopoietic stem cell transplantation (HSCT).
Kinetics of TREO was investigated in phosphate buffers at pH 7.4 and temperature 37?C. The pharmacokinetics of
TREO and its epoxides was studied in rabbits. The validated HPLC method with refractometric and UV detection was applied
for determination of TREO, S, S-EBDM and S,S-DEB.
Transformation of TREO was the best described by kinetic model assuming two first order reactions: TREO → S,S-
EBDM → S,S-DEB as well as first order reactions of hydrolityc decomposition of S,S-EBDM and S,S-DEB.
Formation parameters of S,S-EBDM (t
1.5 h) and S,S-DEB (t
3.3 h), and elimination of TREO (t
1.6 h), S,S-EBDM
0.069 h) and S,S-DEB (t
0,046h) showed that after administration of TREO, both its active transformers demonstrate
a formation-limited disposition. Then elimination of these epoxides proceeds at the same rate as TREO, but amounts of the
transformers in the rabbits are much lower than TREO. It seems to explain the low levels of S,S-EBDM and S,S-DEB in plasma of
patients after administration of TREO before HSCT.
Franciszek Gł?wka has completed his Ph.D. at Poznan University of Medical Sciences (PUMS) and postdoctoral traineeship from Division of
Biomedical Sciences Imperial College, London. He is professor and head of Department Physical Pharmacy and Pharmacokinetics, and Assistant
Dean for Pharmacy Education, Pharm.D Program at PUMS. His fields of interests are bioanalysis of drugs, metabolites and endogenous steroids,
stereoselective pharmacokinetics, therapeutic drug monitoring, pharmacogenetics and biopharmacy. He has published more than 50 papers in
reputed international journals and over 80 contributed oral and poster presentations at national and international scientific meetings.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals